Ocular Genetic Diagnostic Market Report 2026

The ocular genetic diagnostic market size has grown strongly in recent years. It will grow from $1.07 billion in 2025 to $1.18 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to increasing prevalence of inherited ocular conditions, advances in sequencing technologies, growth of specialized ophthalmic clinics, rising awareness of genetic eye disorders, expansion of diagnostic laboratory capabilities.

The ocular genetic diagnostic market size is expected to see strong growth in the next few years. It will grow to $1.67 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing demand for personalized ophthalmic treatments, rising adoption of whole genome sequencing, expansion of preventive genetic screening programs, growing integration of ai in genetic interpretation, increasing investments in precision ophthalmology. Major trends in the forecast period include increasing adoption of comprehensive genetic screening panels, growing use of next-generation sequencing in ophthalmology, expansion of early diagnosis for inherited eye disorders, rising integration of genetic counseling services, enhanced focus on precision eye care.

The increasing prevalence of eye diseases is expected to propel the growth of the ocular genetic diagnostic market going forward. Eye diseases can impair vision if untreated and are rising due to increased digital screen use. Ocular genetic diagnostics enable early detection of inherited eye conditions, improving diagnosis and management. For instance, in February 2025, over 51.9 million US adults reported vision difficulties. Therefore, increasing eye disease prevalence is driving the growth of the ocular genetic diagnostic market.

Leading companies operating in the ocular genetic diagnostic market are focusing on developing advanced services, such as clinical services, to improve early detection, enhance diagnostic accuracy, and support personalized treatment for inherited eye diseases. A clinical service refers to a healthcare activity delivered by qualified professionals to assess, diagnose, treat, and manage patient health conditions. For instance, in October 2024, the Singapore National Eye Centre (SNEC), a Singapore-based public-sector specialty eye hospital, launched the Ocular Genetics Service (OGS), a dedicated clinical service designed to provide specialized care for patients with hereditary eye conditions. This service integrates genetic testing, counselling, and customized clinical management within a single care pathway, enabling timely diagnosis and intervention for rare genetic eye disorders. By bringing together multidisciplinary expertise, the OGS improves diagnostic precision and allows patients to receive personalized care plans based on their genetic profile. Such service launches highlight a broader shift in the ocular genetic diagnostics market toward precision medicine and patient-centered care models.

In October 2024, Ocuphire Pharma Inc., a US-based ophthalmic biopharmaceutical company, acquired Opus Genetics Inc. for an undisclosed amount. Through this acquisition, Ocuphire expanded its pipeline into inherited retinal diseases by gaining access to Opus Genetics’ gene therapy programs targeting rare ocular genetic disorders. This move positions Ocuphire as a more diversified ophthalmology company by combining late-stage small-molecule assets with early-stage gene therapy programs. Opus Genetics Inc. is a US-based company developing therapies for inherited retinal diseases.

Major companies operating in the ocular genetic diagnostic market are Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Illumina Inc., The Children's Hospital of Philadelphia, University of Iowa Hospitals and Clinics, PerkinElmer Inc., Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., ARUP Laboratories Inc., Invitae Corporation, Spark Therapeutics Inc., GeneDx LLC, Blueprint Genetics Oy, Medgenome Labs Inc., Centogene NV, PreventionGenetics LLC, Molecular Vision Laboratory LLC, Casey Eye Institute, Moorfields Eye Hospital & UCL Institute of Ophthalmology.

North America was the largest region in the ocular genetic diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ocular genetic diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ocular genetic diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the ocular genetic diagnostic market by increasing costs of imported sequencing instruments, reagents, bioinformatics software, and laboratory automation systems. Diagnostic laboratories and hospitals in North America and Europe are most affected due to reliance on imported genomic technologies, while Asia-Pacific faces higher costs for test kits and sequencing consumables. These tariffs are increasing diagnostic service prices and slowing lab expansion. However, they are also driving local production of test kits, regional sequencing facilities, and domestic bioinformatics solution development.

The ocular genetic diagnostic market research report is one of a series of new reports that provides ocular genetic diagnostic market statistics, including ocular genetic diagnostic industry global market size, regional shares, competitors with a ocular genetic diagnostic market share, detailed ocular genetic diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the ocular genetic diagnostic industry. This ocular genetic diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ocular genetic diagnostic refers to a specialized discipline focused on identifying and evaluating inherited genetic variations linked to eye health and vision. It involves the systematic analysis of genetic factors that contribute to ocular disorders, with the goal of determining their hereditary origins.

The primary test types in ocular genetic diagnostics are single gene testing, panel testing, whole exome sequencing, and whole genome sequencing. Single gene testing, also referred to as singleton testing, analyzes one specific gene at a time when a particular mutation is suspected based on clinical indicators or family history. Technology types include sequencing technologies, polymerase chain reaction (PCR), microarray technology, and next-generation sequencing (NGS). Applications include retinal disorders, cataract diagnosis, inherited ocular diseases, and age-related macular degeneration and are used by end-users such as hospitals, diagnostic laboratories, academic and research institutes, and others.

The ocular genetic diagnostic market consists of revenues earned by entities by providing services such as molecular diagnostic services, genetic counseling services, risk assessment services, and customized genetic report services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ocular genetic diagnostic market also includes sales of genetic testing kits, laboratory reagents, and consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.